Transgenomic opens pharmacogenomics lab in China

USA-based Transgenomic, a global genetic analysis and services company, has entered into a laboratory services agreement with the Guangzhou Family Planning Center in Guangzhou, China. Under this accord, Transgenomic will partner with the Guangzhou Laboratory to provide pharmacogenomic analyses within the latter for pharmaceutical companies who choose to pursue clinical trials in China. The company has already equipped the facility with the instrument system technology needed to provide these sophisticated pharmacogenomics services.

"Our partnership with the Guangzhou laboratory, coupled with our expanding expertise in conducting pharmacogenomics studies for pharmaceutical companies opens a new door of opportunity for our Pharmacogenomics business," said Craig Tuttle, Transgenomic chief executive. "Many of our pharmaceutical partners are interested in pursuing clinical trials in China. Under Chinese law, samples collected in China must be tested in China. The Guangzhou laboratory provides the facility to enable us to offer our pharmaceutical customers the testing capabilities they seek as they expand their clinical trial efforts to Asia, opening significant new clinical testing opportunities for us and strengthening our position as a leading supplier to our pharmaceutical partners in their worldwide efforts to bring new drugs to market," he added.